Novel anti-igf-ir antibodies and uses thereof
CA 2473039 C · Owner: Pierre Fabre Medicament · Inventors: Goetsch, Liliane; Corvaia, Nathalie; Leger, Olivier
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to novel antibodies capable of binding specifically to the human Insulin-like Growth Factor-I Receptor (IGF-IR) in particular monoclonal of murine origin chimeric and humanized as well as the amino and nucleic acid sequences coding for said antibodies. The invention also concerns the use of said antibodies as medicine for prophylactic and/or therapeutic treatments of cancers as well as methods or kit for diagnosis of diseases related to overexpression of the IGF-IR receptor. The invention further concerns products and/or compositions containing such antibodies combined with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or conjugates with toxins and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 20, 2003 and granted September 23, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 20, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 20, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.